

1 SARS-CoV-2 Receptor Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19

2 Vaccination, Jamaica

3

4 Ynolde E. Leys<sup>1</sup>, Magdalene Nwokocha<sup>2</sup>, Jerome P. Walker<sup>1</sup>, Tiffany R. Butterfield<sup>1</sup>, Velesha

5 Frater<sup>1</sup>, Tamara K. Thompson<sup>3</sup>, Mark Anderson<sup>4</sup>, Gavin A. Cloherty<sup>4</sup>, Joshua J. Anzinger<sup>1,5 \*</sup>

6

7 <sup>1</sup>The University of the West Indies, Department of Microbiology, Kingston, Jamaica, West

8 Indies

9 <sup>2</sup>The University of the West Indies, Department of Pathology, Kingston, Jamaica, West Indies

10 <sup>3</sup>The University of the West Indies, Department of Medicine, Kingston, Jamaica, West Indies

11 <sup>4</sup>Abbott Diagnostics, Infectious Diseases Research, Abbott Park, Illinois, USA

12 <sup>5</sup>Global Virus Network, Baltimore, MD, United States of America

13

14

15 \* Address correspondence to Joshua Anzinger, Department of Microbiology, The University of

16 the West Indies, Mona, Kingston 7, Jamaica. E-mail: [joshua.anzinger@uwimona.edu.jm](mailto:joshua.anzinger@uwimona.edu.jm) Phone:

17 +1 876-977-2206

18

19 Running Head: SARS-CoV-2 RBD IgG Response to AZD1222, Jamaica (60 characters with

20 spaces)

21 Keywords: COVID-19; SARS-CoV-2; Antibody; RBD; Vaccine; AstraZeneca; AZD1222;

22 Caribbean; Jamaica

23 Number of Figures: 1

24 Number of Tables: 2

25 Number of Supplementary Files: 4

26

27 Abstract Word Count: 148

28 Text Word Count: 1459

29 **Abstract (150 words)**

30 The Caribbean region is lacking an assessment of the antibody response and side effects  
31 experienced after AstraZeneca COVID-19 vaccination (AZD1222). We examined SARS-CoV-2  
32 spike receptor binding domain (RBD) IgG levels and reported side effects in a Jamaican  
33 population after AZD1222 vaccination. Median RBD IgG levels for persons without evidence of  
34 previous SARS-CoV-2 infection were 43.1 bIU/mL after 3-7 weeks post first dose, rising to  
35 100.1 bIU/mL 3-7 weeks post second dose, and falling 46.9 bIU/mL 16-22 weeks post second  
36 dose. The median RBD IgG level 2-8 weeks after symptom onset for unvaccinated SARS-CoV-2  
37 infected persons of all disease severities was 411.6 bIU/mL. Common AZD1222 side effects  
38 after first dose were injection site pain, headache and chills. Most persons reported no side  
39 effects after second dose. AZD1222 is widely used across the English-speaking Caribbean and  
40 the study provides evidence for its continued safe and effective use in vaccination programs.

41 **Text**

42 The antibody response to COVID-19 vaccination is considered to be of critical importance for  
43 protection from COVID-19, especially severe manifestations.<sup>1</sup> Generally, antibody responses to  
44 vaccination can differ depending on the population examined,<sup>2</sup> and ideally should be assessed for  
45 each population. All Caribbean Community (CARICOM) member states have received  
46 AstraZeneca vaccines (AZD1222) through COVAX and/or donations, representing the majority  
47 of all vaccine types.<sup>3</sup> Thus far, there have been no studies examining the antibody response to  
48 AZD1222 in the Caribbean, necessitating public health decisions based on data from different  
49 populations that may use different intervals between vaccine doses.

50

51 Jamaica was the first Caribbean country to receive AstraZeneca COVID-19 vaccines via  
52 COVAX, with the first administered on March 10, 2021, exactly one year after the first  
53 confirmed case in the country.<sup>4</sup> In this study we examined the antibody response and side effects  
54 experienced after AZD1222 for a group of initial vaccinees at the University of the West Indies  
55 and University Hospital of the West Indies, Jamaica, and compared responses to unvaccinated  
56 SARS-CoV-2 infected persons. Participants were primarily healthcare workers and faculty but  
57 also included other persons associated with both institutions. Antibody responses were assessed  
58 for persons receiving AZD1222 first doses from March 10-April 27, 2021. Second dose  
59 appointments in Jamaica were made available two calendar months after first vaccination, with  
60 full dose AZD1222 ( $5 \times 10^{10}$  viral particles) offered exclusively for these months. This study was  
61 approved by the University of the West Indies Mona Campus Research Ethics Committee  
62 (CREC-MN.150 20/21).

63

64 Antibody responses to vaccination were determined using an Abbott ARCHITECT *i2000sr*  
65 instrument (Abbott Laboratories, Abbott Park, Illinois) for the SARS-CoV-2 IgG II Quant and  
66 Abbott ARCHITECT SARS-CoV-2 IgM assays: both identified antibodies specific for the spike  
67 protein. The SARS-CoV-2 IgG II Quant assay measured antibodies against the spike receptor  
68 binding domain (RBD), the domain responsible for binding to ACE2 receptors and a major target  
69 of neutralizing antibodies.<sup>5</sup> SARS-CoV-2 IgG II Quant assay results were reported in WHO  
70 binding international units per milliliter (bIU/mL) by multiplying the arbitrary units per milliliter  
71 (AU/mL) value by 0.142.<sup>6</sup> Past infection with SARS-CoV-2 was determined using the Abbott  
72 ARCHITECT SARS-CoV-2 IgG assay that identified nucleocapsid-specific IgG. A lower cutoff  
73 ( $\geq 0.4$  S/CO) than the manufacturer's instructions was used for the SARS-CoV-2 nucleocapsid-  
74 specific IgG assay to increase sensitivity as described previously.<sup>7</sup> All samples in this study were  
75 tested with all three assays. SARS-CoV-2 IgG II Quant and IgM assays were considered positive  
76 according to the manufacturer's instructions ( $\geq 50$  AU/mL and  $\geq 1.0$  S/CO, respectively).

77  
78 A total of 71 AZD1222 vaccinated persons were assessed, 52.1% being males, with an average  
79 age of 49.9 years (Table 1). The average time between doses was  $9.0 \pm 0.8$  weeks. Three weeks  
80 after first dose all but one person was positive for SARS-CoV-2 RBD IgG and most persons with  
81 longitudinal samples showed increased RBD IgG after the second AZD1222 dose that decreased  
82 over time (Figure 1A). In participants without serological evidence of previous SARS-CoV-2  
83 infection, median RBD IgG responses were 43.1 bIU/mL (303.5 AU/mL) after 3-7 weeks post  
84 first dose, rising to 100.1 bIU/mL (704.6 AU/mL) 3-7 weeks post second dose, and falling to  
85 46.9 bIU/mL (330.3 AU/mL) 16-22 weeks post second dose (Figure 1B and Table 1). The only

86 person not showing evidence of RBD IgG antibodies (<50 AU/mL) after the second AZD1222  
87 dose was notable for an age >80 years (the only participant age >80 years).  
88  
89 Similar to previous studies with AZD1222 and Pfizer-BioNTech COVID-19 (BNT162b2)  
90 vaccines,<sup>8,9</sup> most vaccinated persons with evidence of previous SARS-CoV-2 infection showed  
91 greater RBD IgG levels after first dose than persons vaccinated without evidence of previous  
92 SARS-CoV-2 infection (Supplemental Figure 1). The three greatest RBD IgG responses after  
93 AZD1222 vaccination were from persons with SARS-CoV-2 PCR-confirmed infection within 2  
94 months prior to receiving the first dose (Supplemental Table 1). In total, twelve persons showed  
95 serological evidence of SARS-CoV-2 infection, with four persons experiencing COVID-19  
96 (three SARS-CoV-2 PCR-confirmed and one previously antibody positive) and eight not  
97 reporting COVID-19. One person showed serological evidence of SARS-CoV-2 infection after  
98 first but before second AZD1222 dose and three persons showed evidence of SARS-CoV-2  
99 breakthrough infection between 3 and 18 weeks after the second dose of AZD1222  
100 (Supplemental Figure 2). None of the persons reported COVID-19 symptoms. Positive SARS-  
101 CoV-2 IgM results were generally not observed after AZD1222 vaccination (Supplemental  
102 Figure 3) and index values were much lower than we previously reported for SARS-CoV-2  
103 natural infection.<sup>10</sup>  
104  
105 For comparison to AZD1222 vaccination, the RBD IgG response was assessed with convalescent  
106 sera from 21 unvaccinated SARS-CoV-2 PCR-confirmed persons, with 52.4% male, and an  
107 average age of 54.1 years (Table 1). RBD IgG responses were assessed 2-8 weeks after  
108 symptoms onset (or positive PCR test for asymptomatic infections) for unvaccinated persons

109 infected during the initial (April 2020-January 2021) and third waves (July 2021-September  
110 2021) (Table 1 and Figure 1B). Both waves were grouped together, as median RBD IgG  
111 responses were not statistically different (Mann-Whitney test,  $p > 0.999$ ) when comparing  
112 severe-critical infections for the two waves (only severe-critical infection data was available for  
113 the third wave). The median RBD IgG antibody response for unvaccinated PCR-confirmed  
114 SARS-CoV-2 infected persons was 411.6 bIU/mL (2,898.9 AU/mL) when including all WHO  
115 disease severities. Higher RBD IgG antibody levels were correlated with disease severity as  
116 assessed by Spearman's correlation ( $\rho = 0.44$ ,  $p = 0.04$ ), in agreement with previous  
117 observations.<sup>11</sup> No correlation was identified for RBD IgG levels and age or sex for unvaccinated  
118 SARS-CoV-2 infected persons as assessed by Spearman's correlation.

119  
120 Most persons reported side effects and treatment after first AZD1222 dose, whereas after second  
121 dose fewer persons reported side effects and they were of shorter duration (Table 2). Spearman's  
122 correlation indicated that myalgia, arthralgia and eye pain were each individually correlated with  
123 RBD IgG levels ( $\rho = 0.385$ ,  $p = 0.02$ ;  $\rho = 0.374$ ,  $p = 0.03$ ,  $\rho = 0.368$ ,  $p = 0.03$ , respectively) after  
124 first dose but no correlation between any side effect and RBD IgG levels was identified after  
125 second dose. Side effects after first dose were mostly similar to those reported for a phase 1/2  
126 safety and immunogenicity study in a UK population, with the exception of lower percentages  
127 reporting fatigue (18% vs 70-71%) and myalgia (16% vs 48-60%) in this study compared to the  
128 UK study.<sup>12</sup>

129  
130 This study provides the first assessment of the antibody response to AZD1222 vaccination in the  
131 Caribbean region, and provides important information related to common side effects

132 experienced. Most importantly, we show that almost all (70/71) AZD1222 vaccine recipients in  
133 this study developed SARS-CoV-2 RBD IgG that remained positive up to 16-22 weeks after  
134 second AZD1222 dose.

135  
136 We observed a lower RBD IgG response to AZD1222 than a previous study in the UK that  
137 showed a median SARS-CoV-2 RBD IgG of 435 AU/mL for samples collected >21 days after  
138 the first AZD1222 dose using the same Abbott SARS-CoV-2 IgG II Quant assay.<sup>8</sup> In our study  
139 we showed a more modest median response of 303.5 AU/mL 3-7 weeks after the first AZD1222  
140 dose that could possibly be explained by a younger age of the UK population examined and/or  
141 genetic or other differences between populations.

142  
143 The average time to second AZD1222 dose in this study was 9 weeks. The duration between  
144 doses can affect the antibody response, with previous studies showing that receipt of the second  
145 AZD1222 dose at 12 weeks resulted in greater antibody levels compared to boosting at 8  
146 weeks.<sup>13</sup> More recent data showed that extended periods between first dose and second dose  
147 greater >12 weeks is associated with higher antibody titers.<sup>14</sup> Although extended times from  
148 initial dosing to second dose may be beneficial, consideration must be given for the extent of  
149 SARS-CoV-2 circulation within populations that may favor shorter intervals between doses.

150  
151 This study was limited by the modest sample size and neutralizing antibody testing that was not  
152 done. While the SARS-CoV-2 IgG II Quant assay measures IgG antibodies against the spike  
153 RBD, a key domain associated with neutralization, the assay does not directly measure  
154 neutralizing antibodies. However, RBD IgG levels as measured with the Abbott SARS-CoV-2



155 IgG II Quant have previously been shown to be correlated with neutralizing antibodies,<sup>15</sup> and  
156 recent studies show that RBD IgG antibody levels are associated with vaccine efficacy.<sup>16,17</sup>  
157 These studies examining correlates of protection indicate the potential utility of measuring RBD  
158 IgG antibody levels in the broader population. Future assessment of a larger, nationally  
159 representative Jamaican population with assessment of neutralizing antibodies would provide  
160 more generalizable information and should be considered by public health officials.

161  
162 In conclusion, our study shows that AZD1222 vaccination is associated with mild side effects in  
163 the Jamaican population and almost always results in RBD IgG that is sustained for at least 22  
164 weeks after vaccination, providing evidence-based support for the continued usage of AZD1222  
165 in the English-speaking Caribbean.

166 Acknowledgements: As Global Infectious Diseases Scholars, Ynolde Leys and Tiffany  
167 Butterfield received mentored research training in the development of this manuscript. This  
168 training was supported in part by the University at Buffalo Clinical and Translational Science  
169 Institute award UL1TR001412 and the Global Infectious Diseases Research Training Program  
170 award D43TW010919. The content is solely the responsibility of the authors and does not  
171 necessarily represent the official views of the Clinical and Translational Science Institute or the  
172 National Institutes of Health.

173  
174 Financial Support: This research was funded by the University Hospital of the West Indies and  
175 Abbott Laboratories.

176  
177 Disclosure: Gavin Cloherty and Mark Anderson are employees and shareholders of Abbott  
178 Laboratories.

179  
180 Authors' addresses: Ynolde E. Leys, Velesha Frater, Joshua J. Anzinger, Department of  
181 Microbiology, The University of the West Indies, Mona, Kingston, Jamaica, E-mails:  
182 [ynolde.leys@gmail.com](mailto:ynolde.leys@gmail.com), [velesha\\_92frater@hotmail.com](mailto:velesha_92frater@hotmail.com), [joshua.anzinger@uwimona.edu.jm](mailto:joshua.anzinger@uwimona.edu.jm).  
183 Magdalene Nwokocha, Department of Microbiology, The University of the West Indies, Mona,  
184 Kingston, Jamaica, E-mail: [magdanwokocha@yahoo.com](mailto:magdanwokocha@yahoo.com). Mark Anderson, Gavin Cloherty,  
185 Infectious Diseases Research, Abbott Diagnostics, Abbott Park, IL, USA, E-mails:  
186 [mark.anderson6@abbott.com](mailto:mark.anderson6@abbott.com), [gavin.cloherty@abbott.com](mailto:gavin.cloherty@abbott.com)

187

## 188 **References**

- 189 1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K,  
190 Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of  
191 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. Published online  
192 2021:1-7.
- 193 2. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination.  
194 *Community Genet*. 2007;10(4):201-217. doi:10.1159/000106559
- 195 3. *COVID-19 Vaccine Update Supplement.*; 2021.  
196 [https://www.carpha.org/Portals/0/Documents/COVID-19 Vaccine Updates/CARPHA](https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20035%20September%206,%202021.pdf)  
197 *COVID-19 Vaccine Update 035 September 6, 2021.pdf*
- 198 4. Christie CDC, Thompson T, Webster-Kerr K. COVID-19 War Games in the Caribbean–  
199 Round One. *Pandemic Case Stud Opin*. 2020;1(4):68-76.
- 200 5. Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of  
201 COVID-19. *Cell Mol Immunol*. Published online 2021:1-14.
- 202 6. Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G, Woclawek-  
203 Potocka I, Lukaszuk A, Rabalski L. Usefulness of IVD Kits for the Assessment of SARS-  
204 CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination. *Vaccines*.  
205 2021;9(8):840.
- 206 7. Buss LF, Prete CAJ, Abraham CMM, Mendrone AJ, Salomon T, de Almeida-Neto C,  
207 França RFO, Belotti MC, Carvalho MPSS, Costa AG, Crispim MAE, Ferreira SC, Fraiji  
208 NA, Gurzenda S, Whittaker C, Kamaura LT, Takecian PL, da Silva Peixoto P, Oikawa  
209 MK, Nishiya AS, Rocha V, Salles NA, de Souza Santos AA, da Silva MA, Custer B,  
210 Parag K V, Barral-Netto M, Kraemer MUG, Pereira RHM, Pybus OG, Busch MP, Castro

- 211 MC, Dye C, Nascimento VH, Faria NR, Sabino EC. Three-quarters attack rate of SARS-  
212 CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*.  
213 2021;371(6526):288-292. doi:10.1126/science.abe9728
- 214 8. Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, Jesuthasan G, O'Donnell D,  
215 Howarth A, Hatch SB, Marsden BD, Jones EY, Stuart DI, Ebner D, Hoosdally S, Crook  
216 DW, Peto TEA, Walker TM, Stoesser NE, Matthews PC, Pouwels KB, Walker AS,  
217 Jeffery K. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and  
218 Oxford-AstraZeneca vaccines by previous infection status. *Clin Microbiol Infect Off Publ*  
219 *Eur Soc Clin Microbiol Infect Dis*. Published online June 2021.  
220 doi:10.1016/j.cmi.2021.05.041
- 221 9. Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J. SARS-CoV-2 Antibody  
222 Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of  
223 the BNT162b2 Vaccine. *JAMA Netw Open*. 2021;4(8):e2119741-e2119741.  
224 doi:10.1001/jamanetworkopen.2021.19741
- 225 10. Butterfield TR, Bruce-Mowatt A, Phillips YZR, Brown N, Francis K, Brown J, Walker JP,  
226 McKnight NAL, Ehikhametalor K, Taylor DK, Bruce CA, McGrowder D, Wharfe G,  
227 Sandiford SL, Thompson TK, Anzinger JJ. Assessment of commercial SARS-CoV-2  
228 antibody assays, Jamaica. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*.  
229 2021;105:333-336. doi:10.1016/j.ijid.2021.02.059
- 230 11. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H,  
231 Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham  
232 TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL,  
233 Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA,

- 234 Boyd SD. Defining the features and duration of antibody responses to SARS-CoV-2  
235 infection associated with disease severity and outcome. *Sci Immunol*. 2020;5(54).  
236 doi:10.1126/sciimmunol.abe0240
- 237 12. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D,  
238 Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B,  
239 Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M,  
240 Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T,  
241 Gilbert SC, Pollard AJ. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine  
242 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised  
243 controlled trial. *Lancet (London, England)*. 2020;396(10249):467-478.  
244 doi:10.1016/S0140-6736(20)31604-4
- 245 13. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B,  
246 Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins  
247 AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ,  
248 Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL,  
249 Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD,  
250 Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall  
251 RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A,  
252 Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie  
253 AJ, Robinson H, Schwarzbald A V, Smith A, Song R, Snape MD, Sprinz E, Sutherland  
254 RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White  
255 T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ. Single-dose  
256 administration and the influence of the timing of the booster dose on immunogenicity and

- 257 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised  
258 trials. *Lancet (London, England)*. 2021;397(10277):881-891. doi:10.1016/S0140-  
259 6736(21)00432-3
- 260 14. Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-  
261 Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S,  
262 Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S,  
263 Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H,  
264 Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Sreaton G, Gilbert SC,  
265 Voysey M, Pollard AJ, Lambe T. Reactogenicity and immunogenicity after a late second  
266 dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised  
267 controlled trials (COV001 and COV002). *Lancet (London, England)*.  
268 2021;398(10304):981-990. doi:10.1016/S0140-6736(21)01699-8
- 269 15. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R,  
270 Wolzt M, Wagner OF, Binder CJ, Haslacher H. Anti-spike protein assays to determine  
271 SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays.  
272 *Microbiol Spectr*. 2021;9(1):e00247-21.
- 273 16. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC,  
274 Hirsch I. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2  
275 infection. *Nat Med*. Published online 2021. doi:[https://doi.org/10.1038/s41591-021-](https://doi.org/10.1038/s41591-021-01540-1)  
276 01540-1
- 277 17. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser DC, Deng W, Zhou H,  
278 Houchens CR, Martins K, Jayashankar L. Immune correlates analysis of the mRNA-1273  
279 COVID-19 vaccine efficacy trial. *medRxiv*. Published online 2021.

280

Table 1  
Participant demographic information and SARS-CoV-2 RBD IgG levels

	Vaccinated				Infected, Unvaccinated
	3-7 Weeks After First AZD1222 Dose	3-7 Weeks After Second AZD1222 Dose	16-22 Weeks After Second AZD1222 Dose	All Time Points After AZD1222	2-8 Weeks After Symptom Onset*
<i>n</i>	39	21	36	71	21
Male	66.7%	76.2%	66.7%	52.1%	52.4%
Mean age ± st. dev	50.4 ± 16.1	54.8 ± 14.5	51.4 ± 16.6	49.1 ± 15.5	54.1 ± 17.4
SARS-CoV-2 RBD IgG AU/mL (IQR), All Samples	305.8 (91.8-792.9)	827.0 (310.5-1,978.9)	342.0 (168.2-681.0)	N/A	2,898.9 (611.1-11,141.1)
SARS-CoV-2 RBD IgG AU/mL (IQR), Excluding Previous Infection	303.5 (91.8-606.2)	704.6 (310.5-1,978.9)	330.3 (146.2-607.1)	N/A	N/A

281 \*2-8 week after positive SARS-CoV-2 PCR test for asymptomatic infections.

Table 2  
Side effects and treatments after AZD1222 vaccination

	1 <sup>st</sup> Dose	2 <sup>nd</sup> Dose
<b>Side Effects</b>		
None	19.6% (11/56)	55.8% (24/43)
Injection site pain	46.4% (26/56)	20.9% (9/43)
Headache	30.3% (17/56)	2.3% (1/43)
Chills	25.0% (14/56)	7.0% (3/43)
Fever	23.2% (13/56)	2.3% (1/43)
Arthralgia	21.4% (12/56)	4.7% (2/43)
Fatigue	17.9% (10/56)	20.9% (9/43)
Myalgia	16.1% (9/56)	-
Eye pain	10.7% (6/56)	-
Weakness	8.9% (5/56)	-
Paresthesia	1.8% (1/56)	2.3% (1/43)
<b>Symptom Duration</b>		
12-24 hr	46.1% (18/39)	68.7% (11/16)
36-48 hr	35.9% (14/39)	18.7% (3/16)
>48 hr	12.8% (5/39)	12.5% (2/16)
<b>Medication</b>		
None	48.2% (27/56)	60.0% (24/40)
Acetaminophen	50.0% (28/56)	37.5% (15/40)
Aspirin	-	2.5% (1/40)
Panadeine F	1.8% (1/56)	-



283 Figure 1. SARS-CoV-2 RBD IgG antibody levels after AZD1222 vaccination and/or SARS-  
284 CoV-2 infection. SARS-CoV-2 RBD IgG was measured with the Abbott ARCHITECT SARS-  
285 CoV-2 IgG II Quant assay with results reported as arbitrary units per milliliter (AU/mL) on the  
286 left y-axis and WHO binding international units per milliliter (bIU/mL) on the right y-axis. A)  
287 Sera from all time points collected after AZD1222 vaccination was assessed for SARS-CoV-2  
288 RBD IgG levels. The vertical dotted line indicates the average time of second AZD1222 dose.  
289 All data points to the right of the vertical dotted were after second AZD1222 dose B) Sera was  
290 collected from AZD1222 vaccinated persons 3-7 weeks after first and second dose, 16-22 weeks  
291 after second dose, and for unvaccinated SARS-CoV-2 PCR-confirmed persons 2-8 weeks after  
292 symptom onset (or PCR confirmation for asymptomatic persons).

